3Negrin R, Stein R, Varidiman J, et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combina- tion with erythropoietin [J]. Blood, 1993,82( 3 ) :737 - 743.
4Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection [ J ] Ann Intern Med,2007,147 (6) :400 - 411.
5Bronchud MH,Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony stimulating factor in patients [ J]. Br J Cancer, 1988,58 ( 1 ) : 64 - 69.
6Giebel S, Thomas X, Hallbook H, et al. The prophylactic use of granniocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL [ J ]. Eur J Cancer, 2012,48 (3) : 360 - 367.
7Welte K, Reiter A, Mempel K, et al. A randomized phase- Ill study of the efficacy of granulocyte colonyhttp stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group [ J ]. Blood, 1996,87 ( 8 ) : 3143 - 3150.
8Heath JA, Steinherz PG, Ahman A, et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study [ J ]. J Clin Oncol, 2003,21 ( 8 ) : 1612 - 1617.
9Hotowiecki J, Giebel S, Krzemiefi S, et al. G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study [ J ]. Leuke Lympho, 2002.43(2) :315 -325.
10Thomas X, Boiron JM, Huguet F, et al. Efficacy of granuloeyte and granulocyte-macrophage colony-stimula- ting factors in the induction treatment of adult acute lymphoblastic leukemia: a muhicenter randomized study [ J ]. nematol J, 2004,5 (5) : 384 - 394.
